U.S. Markets open in 6 hrs 18 mins
  • S&P Futures

    3,602.25
    +26.25 (+0.73%)
     
  • Dow Futures

    29,799.00
    +253.00 (+0.86%)
     
  • Nasdaq Futures

    11,973.00
    +67.75 (+0.57%)
     
  • Russell 2000 Futures

    1,838.50
    +21.40 (+1.18%)
     
  • Crude Oil

    43.48
    +0.42 (+0.98%)
     
  • Gold

    1,827.30
    -10.50 (-0.57%)
     
  • Silver

    23.43
    -0.20 (-0.84%)
     
  • EUR/USD

    1.1876
    +0.0031 (+0.2613%)
     
  • 10-Yr Bond

    0.8570
    0.0000 (0.00%)
     
  • Vix

    22.66
    -1.04 (-4.39%)
     
  • GBP/USD

    1.3364
    +0.0042 (+0.3167%)
     
  • USD/JPY

    104.3100
    -0.1780 (-0.1704%)
     
  • BTC-USD

    18,405.99
    +73.48 (+0.40%)
     
  • CMC Crypto 200

    369.34
    +7.91 (+2.19%)
     
  • FTSE 100

    6,333.84
    0.00 (0.00%)
     
  • Nikkei 225

    26,165.59
    +638.22 (+2.50%)
     

Recap: Regenxbio Q3 Earnings

Benzinga Insights
·1 min read

Shares of Regenxbio (NASDAQ:RGNX) were flat after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share increased 124.47% over the past year to $0.23, which beat the estimate of ($1.01).

Revenue of $98,912,000 higher by 572.87% from the same period last year, which beat the estimate of $21,370,000.

Looking Ahead

Regenxbio hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: Nov 04, 2020

View more earnings on RGNX

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/x4io5q4n

Recent Stock Performance

Company's 52-week high was at $54.97

52-week low: $20.03

Price action over last quarter: down 4.54%

Company Overview

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa).

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.